1087 related articles for article (PubMed ID: 34514436)
1. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
2. Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
Sidler D; Born A; Schietzel S; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Seyed Jafari SM; Radonjic-Hoesli S; Chan A; Hoepner R; Bacher U; Mani LY; Iype JM; Suter-Riniker F; Staehelin C; Nagler M; Hirzel C; Maurer B; Moor MB
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361691
[TBL] [Abstract][Full Text] [Related]
3. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum I; Kared H; Tran TT; Tveter AT; Provan SA; Sexton J; Jørgensen KK; Jahnsen J; Kro GB; Warren DJ; Vaage EB; Kvien TK; Nissen-Meyer LH; Anderson AM; Grødeland G; Haavardsholm EA; Vaage JT; Mjaaland S; Syversen SW; Lund-Johansen F; Munthe LA; Goll GL
Lancet Rheumatol; 2022 Mar; 4(3):e177-e187. PubMed ID: 34977602
[TBL] [Abstract][Full Text] [Related]
7. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
8. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
9. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
11. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: An observational study.
Stambouli N; Bahrini K; Romdhani C; Rebai A; Boughariou S; Zakraoui M; Arfaoui B; Seyli S; Boukhalfa Y; Battikh R; Moussa MB; Labbene I; Ferjani M; Gharssallah H
J Immunol Methods; 2024 May; 528():113665. PubMed ID: 38490578
[TBL] [Abstract][Full Text] [Related]
13. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.
Tolf A; Wiberg A; Müller M; Nazir FH; Pavlovic I; Laurén I; Mangsbo S; Burman J
JAMA Netw Open; 2022 May; 5(5):e2211497. PubMed ID: 35544139
[TBL] [Abstract][Full Text] [Related]
16. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
Mahil SK; Bechman K; Raharja A; Domingo-Vila C; Baudry D; Brown MA; Cope AP; Dasandi T; Graham C; Khan H; Lechmere T; Malim MH; Meynell F; Pollock E; Sychowska K; Barker JN; Norton S; Galloway JB; Doores KJ; Tree T; Smith CH
Lancet Rheumatol; 2022 Jan; 4(1):e42-e52. PubMed ID: 34778846
[TBL] [Abstract][Full Text] [Related]
17. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
[TBL] [Abstract][Full Text] [Related]
18. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Bystrup A; Byg KE; Johansen IS; Mittl K; Rowles W; Mcpolin K; Spencer C; Sagan S; Gerungan C; Wilson MR; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
Mult Scler Relat Disord; 2021 Nov; 56():103251. PubMed ID: 34571415
[TBL] [Abstract][Full Text] [Related]
20. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]